Suvartar (Valsartan) is generally used for long-term management across cardiovascular domains, and may assist with maintaining functional stability in chronic conditions. The therapeutic scope is relevant across three key areas: sustained management of high blood pressure (hypertension), supportive management for chronic heart failure, and stabilization following a heart attack in high-risk patients.

The therapy helps relieve chronically elevated vascular strain that contributes to hypertension, and is applicable in conditions where cardiac inefficiency leads to symptom clusters like shortness of breath and edema (swelling). This supportive management assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods.

This medicine is considered relevant for managing symptoms that interfere with daily functioning in patients requiring therapeutic support for heart conditions.

“The primary benefit is to contribute to easing the overall symptom load and support the patient's capacity for stable daily functioning.”

Quick Fact: Relief for High Blood Pressure Symptoms The medication helps manage the strain on blood vessels, providing the primary benefit of consistent blood pressure lowering for patients requiring long-term maintenance therapy.

Suvartar (valsartan) is an angiotensin II receptor blocker (ARB) used for adults and eligible pediatric patients, but its use is contraindicated and not recommended in several specific populations according to official regulatory documents.

Contraindications and Restrictions

Classification	Population or Condition
Contraindicated	Pregnancy (second and third trimesters)
Contraindicated	Known hypersensitivity to valsartan or any component
Contraindicated	Severe hepatic impairment, biliary cirrhosis, and cholestasis
Contraindicated	Co-administration with aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2)
Not Recommended	Nursing mothers (breastfeeding)
Not Recommended	Children under 6 years of age (FDA) or under 18 years (EMA)
Special Consideration	Patients with severe renal impairment (GFR < 30 mL/min/1.73 m^2)

Use is not recommended in children under 6 years of age. Treatment must be discontinued immediately if pregnancy is detected, due to the risk of fetal harm. Patients with specific degrees of liver or kidney impairment require careful consideration or are outright prohibited from use, as defined in the official labeling.

Official Interaction Profile

The official regulatory profile for Suvartar (Valsartan) documents specific interactions with other medicinal products and substances, primarily driven by additive pharmacodynamic effects and the potential for dual blockade of the Renin-Angiotensin System (RAS).

Contraindicated Co-administration

Co-administration of Suvartar is officially documented as contraindicated with Aliskiren when the patient has a diagnosis of diabetes mellitus or has moderate-to-severe renal impairment (Glomerular Filtration Rate < 60 mL/min). This restriction is based on the increased documented risk of hyperkalemia, hypotension, and changes in renal function.

Exposure and Hyperkalemia Risk

The regulatory label describes a documented interaction with Lithium, where co-administration results in increases in serum lithium concentrations and the risk of associated toxicity. Furthermore, combining Suvartar with agents that increase potassium levels, such as Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene) or Potassium Supplements and Salt Substitutes containing potassium, significantly increases the documented risk of hyperkalemia (elevated serum potassium). This hyperkalemia risk is specifically noted as relevant in heart failure patients.

Renal Function and Antihypertensive Effect

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may result in a documented reduction of the antihypertensive effect and an increased risk of renal impairment. Regarding administration timing, the official label notes the product may be administered with or without food, as no mandatory timing separation rules are documented.

How Suvartar Works: Mechanism of Action

The activity of Valsartan is determined by its ability to specifically antagonize the AT1 receptor, interrupting the Angiotensin II signaling axis.

---

Targeting the AT1 Receptor and Vascular Tone

Valsartan acts as a highly selective antagonist, competitively blocking the Angiotensin II Type 1 ( AT1) receptor found on arterial smooth muscle. By preventing the binding of Angiotensin II, this mechanism interrupts the primary signaling cascade for vasoconstriction. The physiological consequence is arterial smooth muscle relaxation, resulting in reduced Systemic Vascular Resistance (SVR).

---

Modulating Fluid Homeostasis via Aldosterone

The AT1 blockade extends to the adrenal gland, where it reduces the Angiotensin II-driven stimulation of aldosterone release. This reduction in aldosterone diminishes the reabsorption of sodium and water by the kidneys, leading to an effective decrease in overall circulating blood volume. This dual action, characterized by reduced vascular tone and fluid volume, constitutes the core mechanism of action.

How Suvartar (Valsartan) is Used: Official Administration Guidelines

Suvartar is an oral medication, meaning it is taken by mouth as a film-coated tablet in strengths that include 40 mg, 80 mg, 160 mg, and 320 mg. It is essential to follow the specific dosing schedule and administration instructions provided for this medication.

---

Administration and Timing

Instruction	Standard Guidelines
Route & Form	Oral tablets or prepared oral suspension.
Timing Relative to Food	May be administered with or without food.
Dosing Frequency	Once daily for hypertension. Twice daily (in divided doses) for heart failure and following a heart attack (Post-MI).

---

Standard Dosing and Titration

Dosage is initiated at a lower amount and may be gradually increased (titrated) according to the prescribed schedule and patient response, always staying below the maximum recommended dose.

• Hypertension: The usual starting dose is 80 mg or 160 mg once daily, with a maximum recommended dose of 320 mg once daily.
• Heart Failure: Treatment starts at 40 mg twice daily. The dose is incrementally increased over time, typically at intervals of at least two weeks, toward the target maximum of 160 mg twice daily.
• Post-Myocardial Infarction: The starting dose is 20 mg twice daily, initiated as early as 12 hours after the event, and is gradually titrated to a maximum of 160 mg twice daily.

Population-Specific Use

No initial dose adjustment is required for older adults or patients with mild to moderate kidney impairment. However, the dose should not exceed 80 mg daily in patients with mild to moderate non-cholestatic hepatic impairment. Specific dosage calculations based on weight are required for children aged 6 to 16 years with hypertension.

Research Evidence / Overview of Studies for Suvartar

Note: Research evidence for Suvartar is primarily focused on two distinct treatment areas: the new agent Sparsentan (for kidney disease) and the older combination product Valsartan/Hydrochlorothiazide (for high blood pressure). This summary addresses the evidence structure for both.

---

Evidence for Use in Primary IgA Nephropathy (IgAN) at Risk of Rapid Progression

Research for this condition has involved large, multicenter randomized, controlled trials (RCTs). The research primarily explored the use of the agent (Sparsentan, in this context) in adult patients who were diagnosed with IgAN and who were already showing signs of rapid disease progression.

Researchers studied specific, measurable outcomes. The main research monitored outcomes related to systemic or functional imbalance, such as a marker in the urine known as the Urine Protein-to-Creatinine Ratio (UPCR). This marker was studied as a way to monitor changes in kidney function. The studies also monitored the long-term rate of change in estimated kidney function (eGFR) over periods of nearly two years.

Findings describe patterns observed in the studies where the measured UPCR showed differences between the groups receiving the studied drug compared to the comparison group over the short term.

Comparing Suvartar to Other Treatments and Placebo

The primary trials examined how the studied drug compared against another active agent. The research contributes to the broader evidence landscape by providing context on the differences reported in the measured outcomes against one other active agent. Comparative evidence is lacking for a direct, head-to-head comparison against all available treatment options for this condition.

---

Long-Term Studies and Follow-Up Data

Long-term outcomes, particularly for the specific agent studied in IgAN, are not fully characterized beyond the two-year period initially evaluated in the primary trials. While trials for blood pressure components contribute to understanding symptom patterns over many years regarding cardiovascular risk, the evidence is limited regarding the long-term performance and persistence of outcomes for the combination product itself.

---

What Is Still Uncertain About Suvartar Research

Evidence is limited in several key areas. While the short-term measured changes are described in the research, the long-term effects are not fully established, particularly concerning major, irreversible clinical outcomes. Follow-up durations were limited in many of the initial reports. Comparative evidence is lacking against all possible treatment alternatives, and subgroup findings are uncertain when dealing with very small numbers of patients.

Key Studies & References

1. A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)
2. Valsartan/Hydrochlorothiazide: A review of its use in the management of hypertension

Common questions about Suvartar (FAQ)

Q: What is the recommended dose of Suvartar for children (pediatric use)?

According to official product information, the dosage for children being treated for high blood pressure is determined based on their body weight. A healthcare professional starts treatment at a lower amount and adjusts it according to established pediatric guidelines, avoiding the specific details of the dosing schedule.

---

Q: What over-the-counter pain relievers (like ibuprofen) should I avoid while taking Suvartar?

Regulatory documents describe an interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a drug class that includes many common pain relievers. The co-administration of an NSAID with Suvartar may reduce its blood pressure-lowering effect. This combination also carries a documented risk of increasing kidney problems. While official labeling does not list every specific product, the documented interaction involves a risk of reduced blood pressure effect and potential increase in kidney problems.

---

Q: How do I know if I'm having angioedema (a serious side effect)?

Angioedema is a rare but documented serious adverse reaction. This condition is typically characterized by swelling beneath the skin, often in the face, lips, tongue, and throat. If sudden, severe swelling occurs, seek immediate medical attention, as this is considered a clinically significant event.

---

Q: Is it okay to take Potassium Supplements or salt substitutes with Valsartan?

Official regulatory documents indicate that combining Suvartar with potassium supplements, potassium-sparing diuretics, or salt substitutes containing potassium significantly increases the documented risk of hyperkalemia (elevated serum potassium). It is important to review all supplements and salt substitutes with a healthcare professional, as these products increase the documented risk.

---

Q: What should I do if I miss a dose of Suvartar?

Official labeling contains instructions for managing a missed dose. Generally, if a dose is missed, it should be taken if remembered shortly after the scheduled time, but a double dose should never be taken to compensate for a missed dose. Specific instructions should be confirmed via the patient information leaflet or a healthcare provider.

---

Q: How quickly does Valsartan start working after I take the first pill?

Official information indicates that the substantial blood pressure-lowering effect is achieved within two weeks of starting treatment. The maximum reduction in blood pressure is generally reached after four weeks of continuous treatment.

Storage and Disposal Requirements

The storage and disposal of Suvartar (Valsartan) must strictly adhere to regulatory labeling to maintain the product's quality and ensure safety.

---

Storage Conditions

The medicine must be stored at a temperature not above 30 C (86 F). To prevent degradation from moisture, the tablets must be kept in their original container/packaging. Like all medicines, Suvartar must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Suvartar must not be thrown away with household refuse or flushed down the toilet (via wastewater). For proper disposal, the medicine must be returned to a pharmacist who will ensure it is discarded according to local environmental requirements.